{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T15:09:24Z","timestamp":1792336164596,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T00:00:00Z","timestamp":1362182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10928-013-9305-5","type":"journal-article","created":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T01:00:50Z","timestamp":1362186050000},"page":"359-368","source":"Crossref","is-referenced-by-count":14,"title":["Development of a placebo effect model combined with a dropout model for bipolar disorder"],"prefix":"10.1007","volume":"40","author":[{"given":"Wan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Laughren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenther","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,2]]},"reference":[{"issue":"2","key":"9305_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1176\/appi.ajp.163.2.177","volume":"163","author":"AC Swann","year":"2006","unstructured":"Swann AC (2006) What is bipolar disorder? Am J Psychiatry 163(2):177\u2013179","journal-title":"Am J Psychiatry"},{"issue":"1","key":"9305_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/070674370605100102","volume":"51","author":"J Angst","year":"2006","unstructured":"Angst J (2006) Do many patients with depression suffer from bipolar disorder? Canadian journal of psychiatry Revue canadienne de psychiatrie 51(1):3\u20135","journal-title":"Canadian journal of psychiatry Revue canadienne de psychiatrie"},{"key":"9305_CR3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429\u2013435","journal-title":"Br J Psychiatry"},{"issue":"7","key":"9305_CR4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/11590590-000000000-00000","volume":"50","author":"V Pilla Reddy","year":"2011","unstructured":"Pilla Reddy V, Kozielska M, Johnson M, Vermeulen A, de Greef R, Liu J, Groothuis GM, Danhof M, Proost JH (2011) Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet 50(7):429\u2013450. doi: 10.2165\/11590590-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"9305_CR5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1067\/mcp.2000.110975","volume":"68","author":"HC Kimko","year":"2000","unstructured":"Kimko HC, Reele SS, Holford NH, Peck CC (2000) Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 68(5):568\u2013577","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9305_CR6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/clpt.2009.44","volume":"86","author":"LE Friberg","year":"2009","unstructured":"Friberg LE, de Greef R, Kerbusch T, Karlsson MO (2009) Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 86(1):84\u201391","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9305_CR7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10928-009-9110-3","volume":"36","author":"EY Shang","year":"2009","unstructured":"Shang EY, Gibbs MA, Landen JW, Krams M, Russell T, Denman NG, Mould DR (2009) Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder. J Pharmacokinet Pharmacodyn 36(1):63\u201380","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"23","key":"9305_CR8","doi-asserted-by":"crossref","first-page":"11471","DOI":"10.1073\/pnas.89.23.11471","volume":"89","author":"NH Holford","year":"1992","unstructured":"Holford NH, Peace KE (1992) Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89(23):11471\u201311475","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"9305_CR9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1208\/s12248-009-9123-2","volume":"11","author":"VA Bhattaram","year":"2009","unstructured":"Bhattaram VA, Siddiqui O, Kapcala LP, Gobburu JV (2009) Endpoints and analyses to discern disease-modifying drug effects in early Parkinson\u2019s disease. AAPS J 11(3):456\u2013464","journal-title":"AAPS J"},{"key":"9305_CR10","unstructured":"Panel on Handing Missing Data in Clinical Trials, National Research Council (2010) The prevention and treatment of missing data in clinical trials. The National Academies Press, Washington, DC"},{"issue":"1","key":"9305_CR11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejps.2008.10.025","volume":"36","author":"R Gomeni","year":"2009","unstructured":"Gomeni R, Lavergne A, Merlo-Pich E (2009) Modelling placebo response in depression trials using a longitudinal model with informative dropout. Eur J pharm Sci 36(1):4\u201310. doi: 10.1016\/j.ejps.2008.10.025","journal-title":"Eur J pharm Sci"},{"key":"9305_CR12","unstructured":"Dutta S, Diderichsen P, Liu W (2011) Clinical trial simulation of outcome after accounting for high dropout typical of acute pain studies. Paper presented at the American College of Clinical Pharmacology 40th Annual Meeting, Chicago"},{"issue":"1","key":"9305_CR13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1023249510224","volume":"30","author":"C Hu","year":"2003","unstructured":"Hu C, Sale ME (2003) A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 30(1):83\u2013103","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9305_CR14","doi-asserted-by":"crossref","unstructured":"William-Faltaos D, Chen Y, Wang Y, Gobburu J, Zhu H (2012) Quantification of disease progression and dropout for Alzheimer\u2019s disease. Int J Clin Pharmacol Ther. doi: 10.5414\/CP201787","DOI":"10.5414\/CP201787"},{"key":"9305_CR15","unstructured":"U.S. Food and Drug Administration (2009) The critical path initiative: transforming the way FDA-regulated products are developed, evaluated, manufactured, and used"},{"key":"9305_CR16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev.pharmtox.011008.145613","volume":"49","author":"JV Gobburu","year":"2009","unstructured":"Gobburu JV, Lesko LJ (2009) Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol 49:291\u2013301. doi: 10.1146\/annurev.pharmtox.011008.145613","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"9305_CR17","doi-asserted-by":"crossref","unstructured":"Hutmacher MM, French JL, Krishnaswami S, Menon S (2011) Estimating transformations for repeated measures modeling of continuous bounded outcome data. Stat Med. doi: 10.1002\/sim.4155","DOI":"10.1002\/sim.4155"},{"issue":"4","key":"9305_CR18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10928-011-9205-5","volume":"38","author":"C Hu","year":"2011","unstructured":"Hu C, Yeilding N, Davis HM, Zhou H (2011) Bounded outcome score modeling: application to treating psoriasis with ustekinumab. J Pharmacokinet Pharmacodyn 38(4):497\u2013517. doi: 10.1007\/s10928-011-9205-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9305_CR19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.pharmtox.48.113006.094711","volume":"48","author":"F Benedetti","year":"2008","unstructured":"Benedetti F (2008) Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 48:33\u201360. doi: 10.1146\/annurev.pharmtox.48.113006.094711","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"9305_CR20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2125.2006.02815.x","volume":"63","author":"R Gomeni","year":"2007","unstructured":"Gomeni R, Merlo-Pich E (2007) Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol 63(5):595\u2013613. doi: 10.1111\/j.1365-2125.2006.02815.x","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9305_CR21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/clpt.2009.64","volume":"86","author":"Y Wang","year":"2009","unstructured":"Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J (2009) Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 86(2):167\u2013174","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9305_CR22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10928-008-9088-2","volume":"35","author":"C Dansirikul","year":"2008","unstructured":"Dansirikul C, Silber HE, Karlsson MO (2008) Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn 35(3):269\u2013283. doi: 10.1007\/s10928-008-9088-2","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9305_CR23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-244X-8-65","volume":"8","author":"IA Lipkovich","year":"2008","unstructured":"Lipkovich IA, Houston JP, Ahl J (2008) Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach. BMC Psychiatry 8:65","journal-title":"BMC Psychiatry"},{"issue":"10","key":"9305_CR24","doi-asserted-by":"crossref","first-page":"e48135","DOI":"10.1371\/journal.pone.0048135","volume":"7","author":"KT Hall","year":"2012","unstructured":"Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, Conboy LA, Kelley JM, Kokkotou E, Kaptchuk TJ (2012) Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 7(10):e48135. doi: 10.1371\/journal.pone.0048135","journal-title":"PLoS One"},{"issue":"1","key":"9305_CR25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","volume":"19","author":"GI Papakostas","year":"2009","unstructured":"Papakostas GI, Fava M (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19(1):34\u201340. doi: 10.1016\/j.euroneuro.2008.08.009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"9305_CR26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4088\/JCP.08r04516blu","volume":"71","author":"M Sinyor","year":"2010","unstructured":"Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctot KL (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin psychiatry 71(3):270\u2013279. doi: 10.4088\/JCP.08r04516blu","journal-title":"J Clin psychiatry"},{"issue":"8","key":"9305_CR27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1468-2982.1999.019008699.x","volume":"19","author":"HC Diener","year":"1999","unstructured":"Diener HC, Dowson AJ, Ferrari M, Nappi G, Tfelt-Hansen P (1999) Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia 19(8):699\u2013700","journal-title":"Cephalalgia"},{"issue":"1","key":"9305_CR28","first-page":"53","volume":"43","author":"CH Mallinckrodt","year":"2010","unstructured":"Mallinckrodt CH, Zhang L, Prucka WR, Millen BA (2010) Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 43(1):53\u201372","journal-title":"Psychopharmacol Bull"},{"issue":"1572","key":"9305_CR29","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1098\/rstb.2010.0384","volume":"366","author":"P Enck","year":"2011","unstructured":"Enck P, Klosterhalfen S, Weimer K, Horing B, Zipfel S (2011) The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci 366(1572):1889\u20131895. doi: 10.1098\/rstb.2010.0384","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"4","key":"9305_CR30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.10m06191","volume":"72","author":"NA Khin","year":"2011","unstructured":"Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011) Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 72(4):464\u2013472. doi: 10.4088\/JCP.10m06191","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"9305_CR31","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.11r07539","volume":"73","author":"NA Khin","year":"2012","unstructured":"Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2012) Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry 73(6):856\u2013864. doi: 10.4088\/JCP.11r07539","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-013-9305-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-013-9305-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-013-9305-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:04:05Z","timestamp":1559451845000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-013-9305-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,2]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["9305"],"URL":"https:\/\/doi.org\/10.1007\/s10928-013-9305-5","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,2]]}}}